Treatment
Lenvatinib
5
Conditions
84
Trials
18K
Participants
41%
Average Safety
Condition Evidence
Liver cancer due to alcohol use
5 trials · 1,500 participants
60% effectiveness · 55% safety
Liver cancer due to hepatitis B
8 trials · 1,200 participants
80% effectiveness · 30% safety
Liver cancer due to hepatitis C
30 trials · 8,000 participants
75% effectiveness · 50% safety
Liver cancer due to NASH
5 trials · 2,000 participants
85% effectiveness · 40% safety
Thyroid cancer
36 trials · 5,000 participants
75% effectiveness · 30% safety